Show simple item record

dc.contributor.authorStein, Mark A.
dc.contributor.authorWaldman, Irwin D.
dc.contributor.authorCharney, Elizabeth
dc.contributor.authorAryal, Subhash
dc.contributor.authorSable, Craig
dc.contributor.authorGruber, Reut
dc.contributor.authorNewcorn, Jeffrey H.
dc.date.accessioned2012-07-24T02:10:30Z
dc.date.available2012-07-24T02:10:30Z
dc.date.issued2011-12
dc.identifier.bibliographicCitationStein, M. A., Waldman, I. D., Charney, E., Aryal, S., Sable, C., Gruber, R., & Newcorn, J. H. 2011. Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts. Journal of Child and Adolescent Psychopharmacology, 21(6): 581-588. DOI: 10.1089/cap.2011.0018en
dc.identifier.issn1044-5463
dc.identifier.otherDOI: 10.1089/cap.2011.0018
dc.identifier.urihttp://hdl.handle.net/10027/8411
dc.descriptionThis is a copy of an article published in the Journal of Child and Adolescent Psychopharmacology © 2011 Copyright Mary Ann Liebert, Inc.; Journal of Child and Adolescent Psychopharmacology is available online at: http://www.liebertonline.com. DOI: 10.1089/cap.2011.0018en
dc.description.abstractObjective: To compare the dose effects of long-acting extended-release dexmethylphenidate (ER d-MPH) and ER mixed amphetamine salts (ER MAS) on attention-deficit/hyperactivity disorder (ADHD) symptom dimensions, global and specific impairments, and common adverse events associated with stimulants. Methods: Fifty-six children and adolescents with ADHD participated in an 8-week, double-blind, crossover study comparing ER d-MPH (10, 20, 25–30 mg) and ER MAS (10, 20, 25–30) with a week of randomized placebo within each drug period. Efficacy was assessed with the ADHD Rating Scale-IV (ADHD-RS-IV), whereas global and specific domains of impairment were assessed with the Clinical Global Impressions Severity and Improvement Scales and the parent-completed Weiss Functional Impairment Scale, respectively. Insomnia and decreased appetite, common stimulant-related adverse events, were measured with the parent-completed Stimulant Side Effects Rating Scale. Results: Both ER d-MPH and ER MAS were associated with significant reductions in ADHD symptoms. Improvement in Total ADHD and Hyperactivity/Impulsivity symptoms were strongly associated with increasing dose, whereas improvements in Inattentive symptoms were only moderately associated with dose. About 80% demonstrated reliable change on ADHD-RS-IV at the highest dose level of ERMAS compared with 79% when receiving ER d-MPH. Decreased appetite and insomnia were more common at higher dose levels for both stimulants. Approximately 43% of the responders were preferential responders to only one of the stimulant formulations. Conclusions: Dose level, rather than stimulant class, was strongly related to medication response.en
dc.description.sponsorshipFinancial Support: Investigator-initiated study sponsored by Novartis Pharmaceuticals, with additional support provided by the University of Illinois at Chicago (UIC) Center for Clinical and Translational Science (CCTS), Award Number UL1RR029879 from the National Center for Research Resources. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health.en
dc.language.isoen_USen
dc.publisherMary Ann Lieberten
dc.titleDose Effects and Comparative Effectiveness of Extended Release Dexmethylphenidate and Mixed Amphetamine Saltsen
dc.typeArticleen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record